Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Next Previous
Trial Profile

A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selpercatinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LIBRETTO-321
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 07 Feb 2025 Planned End Date changed from 20 Nov 2025 to 1 Nov 2027.
  • 09 Oct 2022 According to an Innovent Biologics media release, results have been published in Therapeutic Advances in Medical Oncology in July(NSCLC part) and in August (MTC/TC part) in 2022.
  • 09 Oct 2022 According to an Innovent Biologics media release, the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for selpercatinib in patients with RET-driven Lung and Thyroid Cancers. he NDA approval was based on data from the global LIBRETTO-001 study and data from the Chinese patient population in the LIBRETTO-321 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top